VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 5, 2019, at our 2019 annual meeting of shareholders, our shareholders approved (i) an amendment and restatement of our 2013 Stock and Option Plan that, among other things, increases the number of shares of common stock authorized for issuance under this plan by 5.0 million shares and (ii) an amendment and restatement of our Employee Stock Purchase Plan that, among other things, increases the number of shares of common stock authorized for issuance under this plan by 2.0 million shares.
Descriptions of the material terms and conditions of our 2013 Stock and Option Plan and our Employee Stock Purchase Plan are provided in our definitive proxy statement for the 2019 annual meeting of shareholders, which was filed with the Securities and Exchange Commission on April 26, 2019, and are incorporated by reference herein.
Item 5.07. Submission of Matters to a Vote of Security Holders
Our annual meeting of shareholders was held on June 5, 2019. The final voting results were as follows:
About VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX)

Story continues below

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Its marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. It is engaged in various other research and mid- and early-stage development programs, such as programs in the areas of oncology, pain and neurology. Its oncology drug candidates include VX-970, VX-803 and VX-984; pain drug candidates include VX-150 and VX-241, and acute spinal cord injury drug candidate include VX-210.

An ad to help with our costs